Despite outperforming the broader S&P 500 Index over the past year, analysts maintain a cautiously optimistic outlook on IDEXX Laboratories’ future prospects.
Although Thermo Fisher Scientific stock has declined over the past year, it has slightly outperformed other medical device stocks, and analysts remain highly bullish about its prospects.
IDEXX Laboratories has outperformed the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.73%. March E-mini S&P...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.84%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.64%. March E-mini S&P futures (ESH26...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.57%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.42%. March E-mini S&P futures (ESH26...
Achieves fourth quarter revenue growth of 14% as reported and 12% organic, reflecting strong CAG Diagnostics recurring revenue, growing 12% reported and 10% organic. ...
As owners know, caring for ailing pets involves multiple batteries of diagnostic tests. Idexx Laboratories Inc. provides them, observes Jim Woods, editor of Investing Edge.